NEW YORK, Feb 6, 2026, 14:23 EST — Regular session.
Pfizer shares climbed 72 cents, or 2.7%, to $27.22 in afternoon trading Friday, outpacing the SPDR S&P 500 ETF’s roughly 1.7% gain. Roughly 30 million Pfizer shares traded hands.
Pfizer announced that the U.S. Food and Drug Administration has granted Priority Review for its hemophilia drug HYMPAVZI (marstacimab), targeting an approval decision by the second quarter of 2026. This designation trims the usual FDA review period by around four months. The expanded label aims to include patients as young as 6 years old, particularly those with inhibitors that reduce the effectiveness of standard factor replacement therapy.
The stock has been in focus following Pfizer’s launch of the TrumpRx discount program, aimed at more than 30 branded drugs. It targets patients paying out of pocket rather than using insurance. “For far too long, Americans have shouldered a disproportionate share of the global cost of innovation,” CEO Albert Bourla said in the announcement. Pfizer
GoodRx, now part of TrumpRx, is the pricing source for over 30 Pfizer drugs at launch, with more manufacturer deals expected soon. “GoodRx gives manufacturers a proven way to launch discounted cash pricing at scale and extend it directly into TrumpRx,” said Wendy Barnes, GoodRx’s president and CEO. Barchart.com
A White House fact sheet announced that TrumpRx.gov launched Thursday, offering discounts on 40 branded drugs from Pfizer and four other makers who’ve struck “most-favored nation” pricing deals, linking U.S. costs to the lowest prices paid by other developed countries. The administration said more drugs from companies with similar agreements will be added in the months ahead. The White House
Juliette Cubanski, deputy director of the Program on Medicare Policy at KFF, questioned the program’s value for those with insurance, pointing out they already benefit from negotiated prices. Chris Pernie, a spokesperson for Novo Nordisk, argued the initiative broadens access to “authentic, FDA-approved medicines,” highlighting that discounts on GLP-1 drugs — the hormone-mimicking class used to treat obesity and diabetes — are central to the rollout. Reuters
Shares of other major drugmakers linked to the pricing surge also climbed Friday, with Eli Lilly gaining around 2.6%, Novo Nordisk jumping close to 8.1%, and Merck rising just under 2%.
But these discounts and the direct-to-consumer approach come with caveats. BioPharma Dive points out the portal probably won’t move the needle much on drug costs for most Americans using insurance, raising doubts about how much business will actually switch to cash-pay options.
Pfizer investors face a tricky balancing act: HYMPAVZI’s possible label expansion might boost its patient reach, but a new pricing program—while easing costs for some—could drag down revenue per prescription if it grows too large.
Pfizer’s upcoming quarterly report, due April 28, will be the next key moment to gauge management’s outlook, according to Yahoo Finance’s earnings calendar.
Traders will be keeping an eye on early uptake signals from TrumpRx and any new details on HYMPAVZI’s FDA decision timeline, expected in the second quarter, before the next update.
Related articles: NYSE:PFE
